The Filing Desk

Aurinia Pharmaceuticals

AUPH · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

AUPH · Last close · November 13, 2026
$15.73
Value Aurinia Pharmaceuticals yourself

Aurinia Pharmaceuticals' revenue rose 20.4% to $283 million in fiscal 2025. Its operating margin was 37.1%, up from −2.0% a year earlier. Free cash flow was $135 million, up 207.0%. It paid out $98 million in dividends and buybacks, 72% of free cash flow. The diluted share count fell 5.1%.

Aurinia Pharmaceuticals Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001600620-26-000017 Updated
Revenue
$283M
20.4%
Operating margin
37.1%
39.1 pts
Net income
$287M
4893.1%
Free cash flow
$135M
207.0%
Return on equity
59.9%
58.4 pts
Market cap
$2.1B
Nov 13 close
P/E
6.9x
On $2.29 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Aurinia Pharmaceuticals does

Aurinia sells LUPKYNIS (voclosporin), a pill for adults with active lupus nephritis, a serious kidney disease caused by lupus. The company says it was the first FDA-approved oral therapy for this condition, in January 2021. It is also developing aritinercept for other autoimmune diseases.

In the United States Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor. For Europe and Japan it sells inventory to its partner Otsuka under a licensing deal, which also pays milestones and royalties. In 2025 its net product sales were $271.3 million. Lonza makes voclosporin for it under contract.

Aurinia is therefore closely tied to one product. It also repurchased some of its own shares in 2025.

Its biggest risks, as it describes them

  • Depending heavily on the commercial success of LUPKYNIS, its one product.
  • Its sales in Europe and Japan depend on its partner Otsuka meeting its contract duties.
  • Pricing rules and insurance coverage may limit what it earns from LUPKYNIS.
  • Patents covering LUPKYNIS may not hold up, and other companies may claim it infringes theirs.
  • Drug development is long and uncertain, and early aritinercept results may not carry over.
From Aurinia Pharmaceuticals's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2024 to 2025, earnings per share grew 5,075.0% a year and net income 4,851.7% a year, as buybacks cut the share count by 5%.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments23294498380
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage——−33.0x−1.0x24.2x
Current ratio12.6x9.6x5.5x4.6x5.2x
Quick ratio12.2x9.1x5.0x4.2x4.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Aurinia Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $25.1 million of Aurinia Pharmaceuticals shares on the open market, and 1 insider sold $546,373.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 10, 2026Stephen P. RobertsonChief Legal OfficerSold11,939$15.95$190,427Form 4
Aug 21, 2026Stephen P. RobertsonChief Legal OfficerSold20,975$16.97$355,946Form 4
Jun 2, 2026Kevin TangChief Executive Officer, Director, 10% ownerBought206,005$15.28$3.1 millionForm 4
Jun 1, 2026Kevin TangChief Executive Officer, Director, 10% ownerBought343,620$15.28$5.3 millionForm 4
May 29, 2026Kevin TangChief Executive Officer, Director, 10% ownerBought264,981$15.31$4.1 millionForm 4
Mar 3, 2026Kevin TangDirectorBought184,208$14.22$2.6 millionForm 4
Mar 2, 2026Kevin TangDirectorBought199,353$14.26$2.8 millionForm 4
Feb 27, 2026Kevin TangDirectorBought516,439$13.99$7.2 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 4011.5%52.7%68.2%
Altman Z''−0.240.845.18
Accruals ratio−8.8%−7.0%23.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positiveFailPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailPass
Gross margin roseFailFailPass
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Aurinia Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Aurinia PharmaceuticalsFY2520.4%37.1%47.8%———
Xeris BiopharmaFY2543.7%8.5%—19.6%4.2x7Compare
Rigel PharmaceuticalsFY2564.2%42.6%—91.3%−0.8x7Compare
HarrowFY2536.4%11.2%15.8%—5.5x6Compare
Ironwood PharmaceuticalsFY25−15.7%33.3%42.9%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue00005046134176235283
Revenue growth—141.6%10.8%−31.3%15,660.4%−9.0%193.9%30.9%34.0%20.4%
Gross profit———05044128161207250
Research and development14344153505145502132
Operating income−25−47−55−91−104−181−112−92−5105
Net income−23−71−53−88−103−181−108−786287
Diluted EPS (US$)−0.66−0.92−0.63−0.95−0.87−1.40−0.76−0.540.042.07
Diluted shares (millions)35778593118129142143146139
Cash flow
Cash from operations−19−41−52−64−70−158−80−3444136
Capital expenditure0000600100
Free cash flow−19−41−52−64−76−158−80−3444135
Dividends paid0000000000
Share buybacks000000004098
Acquisitions0000000000
Stock-based compensation1477183132453215
Balance sheet at fiscal year end
Cash and short-term investments4017412630627223294498380
Debt incl. finance leases——————————
Total assets57190146324464543471548551752
Total liabilities21243326566465170173170
Shareholders' equity36178136299408479405378378581
Margins and ratios
Gross margin———100.0%100.0%97.6%95.8%91.9%88.0%88.5%
Operating margin−14,466.5%−11,212.4%−11,930.9%−28,598.4%−208.1%−396.3%−83.2%−52.2%−2.0%37.1%
Net margin−13,465.3%−16,935.9%−11,464.1%−27,794.0%−204.9%−396.8%−80.7%−44.5%2.5%101.5%
Free cash flow margin−10,825.4%−9,855.0%−11,153.6%−20,022.6%−150.7%−346.4%−59.5%−19.5%18.8%47.8%
Rule of 40 (growth + FCF margin)—−9,713.4%−11,142.8%−20,054.0%15,509.7%−355.4%134.3%11.5%52.7%68.2%
Return on capital——————————
Return on equity—−66.2%−33.9%−40.7%−29.1%−40.8%−24.5%−19.9%1.5%59.9%
Return on assets—−57.4%−31.6%−37.6%−26.1%−35.9%−21.3%−15.3%1.1%44.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Aurinia Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Aurinia Pharmaceuticals.